Zahir, Hamim
Greenberg, Jonathan
Shuster, Dale http://orcid.org/0000-0003-0260-509X
Hsu, Ching
Watanabe, Kengo
LaCreta, Frank http://orcid.org/0000-0001-8266-5927
Clinical trials referenced in this document:
Documents that mention this clinical trial
Evaluation of Absorption and Metabolism-Based DDI Potential of Pexidartinib in Healthy Subjects
https://doi.org/10.1007/s40262-022-01172-9
Funding for this research was provided by:
Daiichi Sankyo, Inc.
Article History
Accepted: 15 August 2022
First Online: 20 October 2022
Declarations
:
: The work was supported by Daiichi Sankyo, Inc.
: Hamim Zahir reports employment with Daiichi Sankyo, Inc. during the time of the study. Jonathan Greenberg reports employment with and stock/stock options in Daiichi Sankyo, Inc. Dale Shuster reports employment, stock/stock options in, and patents with Daiichi Sankyo, Inc. Ching Hsu reports employment and stock/stock options in Daiichi Sankyo, Inc. Kengo Watanabe reports employment with Daiichi Sankyo, Co., Ltd. Frank LaCreta reports employment with and stock/stock options in Daiichi Sankyo, Inc.
: The studies were conducted in compliance with the ethical principles of the Declarations of Helsinki and the International Conference on Harmonization consolidated Guideline E6 for Good Clinical Practice and approved by the applicable institutional review boards.
: All subjects provided written informed consent prior to study participation.
: Not applicable.
: De-identified individual participant data and applicable supporting clinical study documents may be available upon request at ExternalRef removed/. In cases where clinical study data and supporting documents are provided pursuant to the sponsor’s policies and procedures, the sponsor will continue to protect the privacy of the clinical study participants. Details on data sharing criteria and the procedure for requesting access can be found at this web address: ExternalRef removed.
: Not applicable.